Literature DB >> 11832774

Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion.

Adam Jones1, Chisato Fujiyama, Kevin Turner, David Cranston, Kaye Williams, Ian Stratford, Roy Bicknell, Adrian L Harris.   

Abstract

PURPOSE: It has been previously demonstrated that the angiogenic factor thymidine phosphorylase is elevated significantly in invasive bladder cancer. We report that it is not merely an incidental finding. Thymidine phosphorylase has a functional role in bladder cancer invasion.
MATERIALS AND METHODS: The superficial bladder cancer cell line RT112 was transfected by retroviral techniques to generate the RT112-TP clone that expressed significantly elevated levels of thymidine phosphorylase, comparable to those of invasive human bladder cancers. The empty vector control RT112-EV was generated for comparison. Growth of these transfectants was examined using a new in vitro model of bladder cancer invasion based on de-epithelialized rat bladder and by assessing growth as xenografts in nude mice. The effect of 5-deoxy-5-fluorouridine, a prodrug activated by TP to produce 5-fluorouracil, was also examined.
RESULTS: RT112-TP high thymidine phosphorylase expressing cells invaded into the stroma of the in vitro model but wild-type RT112 and RT112-EV cells did not. This invasion was abolished by 5-deoxy-5-fluorouridine. Invasion correlated with thymidine phosphorylase expression on immunohistochemical testing. There was also a significantly greater xenograft growth rate for RT112-TP than for RT112-EV, confirming the malignant growth advantage conferred by thymidine phosphorylase.
CONCLUSIONS: We demonstrated that thymidine phosphorylase may have a functional role in bladder cancer invasion and the apparent advantage of thymidine phosphorylase expression to tumor cells can be exploited by therapies that utilize prodrugs such as 5-deoxy-5-fluorouridine, which is activated by thymidine phosphorylase and inhibited invasion in our model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832774

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap.

Authors:  Haiyan Lu; Robert S Klein; Edward L Schwartz
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

2.  Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma.

Authors:  N S Brown; E H Streeter; A Jones; A L Harris; R Bicknell
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

3.  No relationship between thymidine phosphorylase (TP, PD-ECGF) expression and hypoxia in carcinoma of the cervix.

Authors:  P Kabuubi; J A Loncaster; S E Davidson; R D Hunter; C Kobylecki; I J Stratford; C M L West
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

4.  Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.

Authors:  Christoph Zielinski; Istvan Lang; Semir Beslija; Zsuzsanna Kahan; Moshe J Inbar; Salomon M Stemmer; Rodica Anghel; Damir Vrbanec; Diethelm Messinger; Thomas Brodowicz
Journal:  Br J Cancer       Date:  2015-12-10       Impact factor: 7.640

5.  Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.

Authors:  M de Bruin; T van Capel; K Van der Born; F A Kruyt; M Fukushima; K Hoekman; H M Pinedo; G J Peters
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.